Document Detail


Mirtazapine augmentation enhances cognitive and reduces negative symptoms in schizophrenia patients treated with risperidone: A randomized controlled trial.
MedLine Citation:
PMID:  21095214     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
This preliminary study aimed to determine if adding mirtazapine to risperidone might improve negative and cognitive symptoms in schizophrenia. In an 8-week, double-blind clinical trial, we randomly assigned 21 stabilized outpatients with schizophrenia undergoing risperidone treatment to adjunctive treatment with either mirtazapine or a placebo. The mirtazapine group exhibited a statistically significant improvement in cognitive function, including vocabulary and immediate memory, and negative symptoms (as measured by negative symptom scales) and showed an adverse effect of 5.83kg mean weight gain. This study suggests augmenting risperidone with mirtazapine can effectively improve both negative and some cognitive symptoms of schizophrenia. RESEARCH HIGHLIGHTS: ► Mirtazapine enhances some cognitive symptoms of schizophrenia. ► Mirtazapine reduces negative symptoms of schizophrenia.
Authors:
Sung Joon Cho; Keunyoung Yook; Borah Kim; Tai Kiu Choi; Kang Soo Lee; Yong Woo Kim; Ji Eun Lee; Shinyoung Suh; Ki Hwan Yook; Sang-Hyuk Lee
Related Documents :
10831024 - Randomized, placebo-controlled pilot study of divalproex sodium in the treatment of acu...
9443524 - A study of enhanced management in patients with treatment-resistant schizophrenia.
12606844 - Flupenthixol versus risperidone: subjective quality of life as an important factor for ...
8526974 - Regional cortical anatomy and clozapine response in refractory schizophrenia.
20478874 - Cannabis use and the course of schizophrenia: 10-year follow-up after first hospitaliza...
17803494 - The effectiveness of antidepressant medication in the management of behaviour problems ...
Publication Detail:
Type:  Journal Article     Date:  2010-11-21
Journal Detail:
Title:  Progress in neuro-psychopharmacology & biological psychiatry     Volume:  35     ISSN:  1878-4216     ISO Abbreviation:  Prog. Neuropsychopharmacol. Biol. Psychiatry     Publication Date:  2011 Jan 
Date Detail:
Created Date:  2011-01-11     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8211617     Medline TA:  Prog Neuropsychopharmacol Biol Psychiatry     Country:  England    
Other Details:
Languages:  eng     Pagination:  208-11     Citation Subset:  IM    
Copyright Information:
Copyright © 2010 Elsevier B.V. All rights reserved.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Hydrogen sulfide reduces mRNA and protein levels of beta-site amyloid precursor protein cleaving enz...
Next Document:  Gender differences in the effects of peroxisome proliferator-activated receptor ?2 gene polymorphism...